Refine
Has Fulltext
- yes (149)
Is part of the Bibliography
- yes (149)
Year of publication
Document Type
- Journal article (103)
- Doctoral Thesis (46)
Keywords
- Tissue Engineering (23)
- tissue engineering (10)
- in vitro (5)
- regenerative medicine (5)
- stem cells (5)
- 3D tissue model (4)
- In-vitro-Kultur (4)
- extracellular matrix (4)
- gene expression (4)
- inflammation (4)
- BMP-2 (3)
- Bordetella pertussis (3)
- In vitro (3)
- Stammzelle (3)
- Zellkultur (3)
- bone regeneration (3)
- chondrocytes (3)
- collagens (3)
- decellularization (3)
- electrospinning (3)
- B cells (2)
- BMP (2)
- Bone morphogenetic protein-2 (2)
- Cancer (2)
- Dünndarm (2)
- Elektrospinnen (2)
- Fibroblasts (2)
- GMP (2)
- Gewebekultur (2)
- Hautmodell (2)
- Hirschsprung disease (2)
- Hyaliner Knorpel (2)
- Implantat (2)
- Kollagen (2)
- Kreuzband (2)
- Ligamentum cruciatum anterius (2)
- Melanom (2)
- Mundschleimhaut (2)
- Neisseria gonorrhoeae (2)
- Osteoarthritis (2)
- Raman-Spektroskopie (2)
- Regenerative Medizin (2)
- SARS-CoV-2 (2)
- Tumormodell (2)
- Validierung (2)
- Vaskularisation (2)
- Vaskularisierung (2)
- Wundheilung (2)
- anthocyanins (2)
- bioengineering (2)
- biological models (2)
- bioreactor (2)
- blood-brain barrier (BBB) model (2)
- burn wound (2)
- cartilage regeneration (2)
- co-culture (2)
- colorectal cancer (2)
- extracellular vesicles (2)
- growth factor beta (2)
- impedance spectroscopy (2)
- infection (2)
- intestinal in vitro model (2)
- invasion (2)
- mesenchymal stem cells (2)
- multiple myeloma (2)
- osteoarthritis (2)
- pancreas (2)
- permeability (2)
- phenotype (2)
- raman spectroscopy (2)
- rat (2)
- reconstructed human epidermis (2)
- scaffolds (2)
- subcutaneous animal model (2)
- targeted therapy (2)
- therapy (2)
- vascularization (2)
- wound healing (2)
- 1st-line treatment (1)
- 3D (1)
- 3D Modell (1)
- 3D Tumormodell (1)
- 3D in vitro Modell (1)
- 3D in vitro model (1)
- 3D in vitro models (1)
- 3D lung tumor tissue models (1)
- 3D model (1)
- 3D models (1)
- 3D scaffolds (1)
- 3D tissue models (1)
- 3D tumour model (1)
- 3D-Elektrode (1)
- 3D-Kultur (1)
- 5-Fluorouracil (1)
- ACL construct (1)
- ATMP (1)
- Adenocarcinom (1)
- Adenokarzinom (1)
- Adenylate cyclase toxin (1)
- Advanced Therapy Medicinal Products (ATMP) (1)
- Akute myeloische Leukämie (1)
- Alternative test methods (1)
- Alternative zum Tierversuch (1)
- Alzheimer′s disease (1)
- Anastomoseninsuffizienz (1)
- Angiogenese (1)
- Anterior Cruciate Ligament (1)
- Antikörper (1)
- Apoptosis (1)
- Arthroseentstehung (1)
- Articular-Cartilage (1)
- Arzneimittel (1)
- Arzneimittelzulassung (1)
- Assay (1)
- Atemwege (1)
- Atemwegsschleimhaut (1)
- Automation (1)
- B cell receptors (1)
- BMP signaling (1)
- BMP-2 delivery (1)
- BRAF mutation (1)
- BRAF-mutant (1)
- BRAF-mutiert (1)
- BSGC (1)
- Bakterielle Nanocellulose (1)
- Bauchspeicheldrüse (1)
- Beta-catenin (1)
- Bindegewebe (1)
- BioVaSc (1)
- Biocompatibility (1)
- Biodegradable polymer scaffolds (1)
- Biodistribution (1)
- Biokompatibilität (1)
- Biomaterial (1)
- Biomechanical Properties (1)
- Biomedical engineering (1)
- Bioreactor (1)
- Bone morphogenetic protein 2 (1)
- Bone tissue engineering (1)
- Brustkrebs (1)
- CCR2 (1)
- CCR4 (1)
- CNS disease (1)
- CYP induction (1)
- CYP inhibition (1)
- CYR61 (1)
- Caco2 cells (1)
- Carcinoma cells (1)
- Cardiac ventricles (1)
- Cell replacement therapy (1)
- Chemicals (1)
- Collagen (1)
- Compressive Properties (1)
- Cytokeratine (1)
- Data acquisition (1)
- Dezellularisierung (1)
- Diabetes mellitus (1)
- Dickdarmtumor (1)
- Diffusion tensor imaging (1)
- Dosis-Wirkungs-Beziehung (1)
- Draize eye test (1)
- Drug testing (1)
- ECM coating (1)
- EMT (1)
- EVs (1)
- Eigenvectors (1)
- Eisenoxid-Nanopartikel (1)
- Electrospinning (1)
- Elektrode (1)
- Enteric nervous system (1)
- Enteric neuropathies (1)
- Entwicklung (1)
- Epidermis (1)
- Epidermismodell (1)
- Episkin (1)
- Epithel (1)
- Eriodictyon californicum (1)
- Extrazellulärmatrix (1)
- Eye irritation (1)
- FGF signaling (1)
- FTIR spectroscopy (1)
- Fibroblast (1)
- Fibrose (1)
- Fluorouracil (1)
- Fremdkörpermodell (1)
- GLP-1 (1)
- GLUTs (1)
- GUT (1)
- Gastrointestinaltrakt (1)
- Gefitinib (1)
- Gelatine (1)
- Gene regulation (1)
- Gewebemodell (1)
- Gewebemodelle (1)
- Glucose transport (1)
- Growth; BMP-2 (1)
- HUVEC (1)
- Halofuginon (1)
- Haut (1)
- Hautverbrennung (1)
- Head and neck cancers (1)
- Heart (1)
- Herzschrittmacher (1)
- Hirschsprung disease liability (1)
- Human Knee (1)
- Human Medial Meniscus (1)
- Humanparasitologie (1)
- Hydrogel (1)
- Hypertrophic pyloric-stenosis (1)
- Hämophilie A (1)
- IL-1ß (1)
- IL-6 (1)
- Immuntherapie (1)
- In vitro skin irritation testing (1)
- In-vitro (1)
- In-vitro-Testsystem (1)
- In-vivo (1)
- Individualisierte Medizin (1)
- Induced pluripotent stem cells (1)
- Induzierte pluripotente Stammzelle (1)
- Infektionsstudien (1)
- Injuries (1)
- Intestinal pseudoobstruction (1)
- Intestinal stem cell (1)
- Invasion (1)
- Irritable bowel syndrome (1)
- Ischämie (1)
- KRAS biomarker signatures (1)
- Kernspintomografie (1)
- Kniegelenk (1)
- Knochenimplantat (1)
- Knochenregeneration (1)
- Knorpelimplantate (1)
- Kohlenstoff (1)
- Kohlenstofffaser (1)
- Krebs <Medizin> (1)
- Kreuzbandersatz (1)
- Kryokonservierung (1)
- Künstliche Ingelligenz (1)
- LCST (1)
- LDH-assay (1)
- Lactatdehydrogenase (1)
- Lgr5 (1)
- Lungentumor (1)
- MRT (1)
- MSC (1)
- Magen (1)
- Magenchirurgie (1)
- Magenkrankheit (1)
- Magnet-Partikel-Spektroskopie (1)
- Magnetic resonance imaging (1)
- Mamma carcinoma (1)
- Mammakarzinom (1)
- Mandibular continuity defects (1)
- Marketing authorisation of pharmaceuticals (1)
- Marrow stromal cells (1)
- Matrix (1)
- Mechanical deformation (1)
- Mechanisms (1)
- Medicine (1)
- Medizinprodukt (1)
- Mesenchymal Stem Cell (1)
- Mesenchymal transition (1)
- Mesenchymale Stammzellen (1)
- Microenvironment (1)
- Mikrowellen (1)
- Minipig (1)
- Model (1)
- Models (1)
- Molekularbiologie (1)
- Mukosamodell (1)
- Multicenter randomized-trial (1)
- Multilayered skin tissue model (1)
- Mundschleimhautäquivalent (1)
- Myofibroblast differentiation (1)
- NK cells (1)
- NMR (1)
- NOTCH (1)
- NOTES <Chirurgie> (1)
- NRAS mutation (1)
- Nanofaser (1)
- Neisseria meningitidis (1)
- Neuartige Arzneimittel (1)
- Neural crest cells (1)
- Nitric-oxide (1)
- OECD guideline (1)
- OLFM4 (1)
- Onchocerca volvulus (1)
- Onchozerkose (1)
- Open source reconstructed epidermis (1)
- Oral squamous cell carcinoma (1)
- Oralmukosa (1)
- Oralmukosamodell (1)
- Oxide synthase gene (1)
- PLGA (1)
- Paclitaxel (1)
- Pancreatic islet (1)
- Pankreas (1)
- Pankreaskarzinom (1)
- Parasitology (1)
- Partikel (1)
- Perforation <Medizin> (1)
- Plattenepithelcarcinom (1)
- Pleuramesotheliom (1)
- Polylactid-co-Glycolid (1)
- Preclinical studies (1)
- Primär-basierte immortalisierte Zelllinie (1)
- Primäre Ziliendyskinesie (1)
- Proliferation (1)
- Protein chemistry (1)
- Protein-Tyrosin-Kinasen (1)
- Präklinische Studien (1)
- QPCR (1)
- RHE (1)
- RT-qPCR (1)
- Rat mynteric plexus (1)
- Real time quantitative PCR (1)
- Receptor (1)
- Repair (1)
- Reperfusion (1)
- Resistenzentwicklung (1)
- Respiratorisches System (1)
- SGLTs (1)
- SIS/MUC (1)
- Salinomycin (1)
- Salmonella (1)
- Salmonella Typhimurium (1)
- Scaffold bone implant (1)
- Sglt1 (1)
- Silikon (1)
- Sinus floor augmentation (1)
- Skin Tissue Engineering (1)
- Slow-transit constipation (1)
- Smooth-muscle-cells (1)
- Squamous-cell carcinoma (1)
- Stammzellforschung (1)
- Stem cells (1)
- Stem-cell biotechnology (1)
- Stimulation (1)
- Swine (1)
- T-Zell-rekrutierende Antikörperkonstrukte (1)
- TEER (1)
- TEER-Wert (1)
- TGF-beta (1)
- TGFβ/BMP signaling (1)
- Targeted therapies (1)
- Term follow-up (1)
- Test system (1)
- Therapeutisches System (1)
- Therapie (1)
- Therapiesimulation (1)
- Tipifarnib (1)
- Tissue (1)
- Tractography (1)
- Triple co-culture (1)
- Tumor models (1)
- Tumorigenicity (1)
- Tumorzelllinien (1)
- Validation (1)
- Vascularized (1)
- Viabilität (1)
- Vivo (1)
- Vorderes Kreuzband (1)
- Wirkstofftestung (1)
- Zell-Migration (1)
- Zelldifferenzierung (1)
- Zellkulturmodell (1)
- acetylsalicylic acid (1)
- acid dissociation (1)
- acute myeloid leukemia (1)
- adenocarcinoma of the lung (1)
- adenylate cyclase toxin (1)
- adhesion (1)
- adults (1)
- aging (1)
- air-liquid interface (1)
- airway epithelia (1)
- airways (1)
- albumins (1)
- algorithm (1)
- alternative to animal testing (1)
- alternatives (1)
- anaesthetics (1)
- anatomy (1)
- animal model (1)
- antagonist (1)
- antennas (1)
- anthocyanin (1)
- antibiotics (1)
- antioxidative (1)
- antitumor peptide (1)
- antiviral activity (1)
- apoptosis (1)
- artificial membrane-permeability (1)
- aspirin (1)
- astaxanthin (1)
- asthmatic bronchial epithelium (1)
- astrocytes (1)
- autologous (1)
- autologous chondrocyte implantation (1)
- automation (1)
- automation & robotics (1)
- bacteria (1)
- bacterial cellulose dressing (1)
- bacterial migration (1)
- bacterial nanocellulose (1)
- bacterial virulence (1)
- barrier models (1)
- benzalkonium chloride (1)
- beta cell (1)
- beta-aminopropionitrile (1)
- beta-cyclodextrin (1)
- betaglycan (1)
- bilberry (1)
- biocompatibility (1)
- biocompatible materials (1)
- bioconjugation (1)
- biofilm (1)
- bioinformatics (1)
- biological barriers (1)
- biological scaffold (1)
- biological scaffolds (1)
- biology (1)
- biomaterial tests (1)
- biomedical engineering (1)
- biomedical materials (1)
- biomimetic 3D tissue model (1)
- bioreactor culture (1)
- biotechnology (1)
- black currant (1)
- blood (1)
- blood glucose regulation (1)
- blood pressure (1)
- blood-brain barrier (1)
- blood-cerebrospinal fluid barrier (1)
- blood‐brain barrier (BBB) (1)
- bone (1)
- bone critical size defect (1)
- bone morphogenetic protein (1)
- bone morphogenetic protein 2 (BMP2) (1)
- bone morphogenetic protein 9 (BMP9) (1)
- bone morphogenetic proteins (1)
- boolean in silico models (1)
- brachtydacyly type A2 (1)
- brain endothelial cells (1)
- brain–liver chip (1)
- breast cancer cells (1)
- calcium fluoride nanoparticles (1)
- cancer dissemination (1)
- cancer treatment (1)
- cancers and neoplasms (1)
- carbon fiber (1)
- cardiac device therapy (1)
- cardiac patch (1)
- cardiac tissue (1)
- cardiovascular (1)
- cardiovascular MR methods (1)
- cartilage (1)
- cartilage defectex vivo model (1)
- cartilage test system (1)
- cell binding (1)
- cell culture (1)
- cell cultures (1)
- cell cycle and cell division (1)
- cell differentiation (1)
- cell engineering (1)
- cell membrane model (1)
- cell metabolism (1)
- cell migration (1)
- cell proliferation (1)
- cellular biology (1)
- cellular microenvironment (1)
- cellular signalling networks (1)
- central nervous system (1)
- ceramide (1)
- chemokine receptor (1)
- chiral resolution (1)
- chondrogenic differentiation (1)
- ciliary neurotrophic factor (1)
- ciliostasis (1)
- circular dichroism (1)
- clinical applications (1)
- collagen sponge (1)
- collagen type I hydrogel (1)
- colllagen (1)
- colon (1)
- colony-stimulating factor (1)
- combination of physical vapor deposition and electrochemical etching (1)
- combinatorial drug predictions (1)
- complexation (1)
- computer modelling (1)
- core depression (1)
- coreceptor (1)
- corneal endothelium (1)
- corneal epithelium (1)
- corneal equivalent (1)
- corneal storage (1)
- covalent coupling (1)
- cross-talk (1)
- cryokonservation (1)
- cryostructured scaffolds (1)
- crystal structure (1)
- crystal-structure (1)
- culture techniques (1)
- cultured (1)
- cyclic adenosine monophosphate (1)
- cycloaddition (1)
- cyclodextrin (1)
- cytokine (1)
- cytokines (1)
- cytotoxicity (1)
- defects (1)
- defined humanized test system (1)
- dendritic cell (1)
- development (1)
- diabetes (1)
- differentiation (1)
- diffusion tensor imaging (1)
- discriminant analysis (1)
- dominant-negative mutatio (1)
- drug (1)
- drug delivery (1)
- drug metabolism (1)
- drug permeability screening (1)
- drug resistance (1)
- dry spinning (1)
- dynamic culture (1)
- dynamic culture conditions (1)
- dystrophic RCS rats (1)
- early diagnosis (1)
- ectopic bone formation (1)
- elastic fibers (1)
- elastin (1)
- electrical and electronic engineering (1)
- electrode scaffold (1)
- embryonic stem cell (1)
- embryonic stem cells (1)
- endothelial cells (1)
- endothelial growth factor (1)
- enteric nervous system (1)
- enzyme metabolism (1)
- epidermis (1)
- epithelial cell culture (1)
- epithelial cells (1)
- equipment and supplies (1)
- establishment (1)
- experimental models of disease (1)
- expression (1)
- eye irritation testing (1)
- factor binding profiles (1)
- factor-VIII (1)
- fibroblast chemotaxis (1)
- fibroblast growth factor (1)
- fibrosis (1)
- filamentous Salmonella Typhimurium (1)
- fixation (1)
- flavonoids (1)
- foreign body reaction (1)
- formalin (1)
- fremdkörper assoziierte Reaktion (1)
- full thickness skin (1)
- functional initiators (1)
- gamma-cyclodextrin (1)
- gastrointestinal tract (1)
- gels (1)
- gene encoding noggin (1)
- gene therapy (1)
- genetic engineering (1)
- glucose (1)
- glycoprotein (1)
- growth and differentiation factor 5 (1)
- hBMSC (1)
- head and neck squamous cell carcinoma (1)
- heart structure (1)
- heart valve (1)
- heparin binding sites (1)
- heptaocytes (1)
- herpesvirus (1)
- highly porous materials (1)
- host (1)
- human (1)
- human airway mucosa tissue models (1)
- human bruchs membrane (1)
- human exposure (1)
- human heptocytes (1)
- human induced pluripotent stem cells (hiPSCs) (1)
- human induced pluripotent stem cells (hiPSCs)human induced pluripotent stem cells (hiPSCs) (1)
- human liver cells (1)
- human nasal epithelial cells (1)
- human osteosarcoma xenografts (1)
- human respiratory epithelial cells (1)
- human tracheo-bronchial epithelial cells (1)
- humane mesenchymale Stammzellen (1)
- human‐induced pluripotent stem cells (hiPSC) (1)
- hyaline cartilage (1)
- hybrid pacemaker (1)
- hyperlipidemia (1)
- hypoxia inducible factor 1 (1)
- immune cell infiltration (1)
- immunotherapeutics (1)
- immunotherapies (1)
- immunotherapy (1)
- implant (1)
- in silico simulation (1)
- in situ guided tissue regeneration (1)
- in vitro Modelle (1)
- in vitro model (1)
- in vitro models (1)
- in vitro-Testsystem (1)
- in vivo (1)
- in vivo experiments (1)
- in vivo study (1)
- in-vitro (1)
- in-vitro models (1)
- in-vitro-Modell (1)
- in-vitro-Testsysteme (1)
- induced pluripotent stem cells (1)
- induction (1)
- infectious disease (1)
- inflammation-induced tissue demage (1)
- inflammatory bowel disease (1)
- inflammatory response (1)
- insulin (1)
- interface (1)
- intestinal enteroids (1)
- intestine (1)
- invasiveness (1)
- invitro (1)
- inflammatory response (1)
- iron metabolism (1)
- irradiation (1)
- islets of Langerhans (1)
- kinetics (1)
- kolorektales Karzinom (1)
- label-free analysis (1)
- laser microdissection (1)
- ligand binding (1)
- ligand-receptor complex (1)
- ligand-receptor promiscuity (1)
- lipids (1)
- liposome (1)
- living cells (1)
- lncRNAs (1)
- long-term (1)
- lower critical solution temperature (1)
- lung and intrathoracic tumors (1)
- lung cancer (1)
- magnetic resonance imaging (MRI) (1)
- malignant tumors (1)
- manufacturing (1)
- measels virus (1)
- measles virus (1)
- medicine (1)
- melanoma metastases (1)
- membrane receptor signaling (1)
- memory (1)
- meningococcus (1)
- mesenchymal cells (1)
- mesenchymal tissues (1)
- metabolic flux analysis (1)
- metallo-supramolecular polymer (1)
- miRNAs (1)
- microbe carrier (1)
- microenvironment (1)
- microparticles (1)
- microphysiological systems (MPS) (1)
- microplastics (1)
- microvascular endothelial cells (1)
- microwave radiation (1)
- midazolam (1)
- migration (1)
- modular tumor tissue models (1)
- moisture balance (1)
- molecular biology (1)
- molecular mechanism (1)
- morphogenetic protein receptors (1)
- motility disorders (1)
- multi-organ chip (1)
- multicellular tumor spheroids (1)
- multifunctional nanoparticles (1)
- multilayered skin (1)
- multimodal imaging (1)
- multipotent fetal neural stem cells (fNSCs) (1)
- murine (1)
- mutagenesis (1)
- myenteric plexus (1)
- nanoparticles (1)
- nanoplastics (1)
- nanotopographical surfaces (1)
- necrosis-factor-alpha (1)
- necrotic cell death (1)
- neural stem-cell (1)
- neurology (1)
- neuronal electrodes (1)
- neurotoxicity (1)
- neurovascular unit in vitro (1)
- neutrophil transmigration (1)
- non-invasive biomarkers (1)
- occupancy (1)
- olfactomedin 4 (1)
- on-a-chip (1)
- open-access database (1)
- open-source epidermis (1)
- oragnoids (1)
- oral mucosa model (1)
- orales Plattenepithelkarzinomäquivalent (1)
- organ-on-a-chip (1)
- organotypic (1)
- osteoblasts (1)
- osteochondral allografts (1)
- osteochondral lesion (1)
- osteogenesis imperfecta (1)
- osteogenic differentiation (1)
- osteoporosis (1)
- outgrowth endothelial cells (1)
- ovarian cancer (1)
- oxidative DNA damage (1)
- pancreatic cancer (1)
- pancreatic differentiation (1)
- perfused hydrogel (1)
- perfusion-based bioreactor system (1)
- peritoneal metastasis (1)
- pharmaceutical applications (1)
- phosphatidylserine (1)
- photoluminescence (1)
- physiology (1)
- platelet-derived growth factor (1)
- pluripotent stem cells (1)
- polymer (1)
- polymerization (1)
- polymers (1)
- polypeptoids (1)
- postpolymerization modification (1)
- precision-cut lung slices (1)
- preclinical drug discovery (1)
- primary cell isolation (1)
- primary cells (1)
- primary ciliary dyskinesia (1)
- primary human hepatocytes (1)
- primary-cell-derived immortalized cell line (1)
- principal component analysis (1)
- progenitor cells (1)
- progenitors (1)
- protein immobilization (1)
- proteins (1)
- pulmonary drug-delivery (1)
- pulmonary imaging (1)
- pulses (1)
- quanititative characterization (1)
- quantification (1)
- randomized clinical trial (1)
- reactive oxygen species (1)
- real time PCR (1)
- receptor type III (1)
- reflection (1)
- rekombinante Spinnseide (1)
- relaxometry (1)
- repair (1)
- respiratory syncytial virus (1)
- responses (1)
- retinal pigment epithelium (1)
- rhBMP–2 (1)
- ring-opening polymerization (1)
- salicylic acid (1)
- salivary gland neoplasia (1)
- salivary gland tumors (1)
- salivary glands (1)
- scaffold (1)
- scanning electron microscopy (1)
- secondary lung tumors (1)
- secondary wound dressing (1)
- segmental collapse (1)
- sevoflurane (1)
- sheep model (1)
- signal integration (1)
- signal specification (1)
- signal tranduction (1)
- signal transduction (1)
- signaling (1)
- signaling pathways (1)
- site directed immobilization (1)
- site-specific immobilization (1)
- skin anatomy (1)
- skin equivalent (1)
- skin equivalents (1)
- skin model (1)
- skin models (1)
- skin physiology (1)
- small intestinal submucosa (1)
- small intestinal submucosa scaffold (1)
- sodium channels (1)
- sol-gel chemistry (1)
- solid tumors (1)
- solubility (1)
- sphingosine-1-phosphate (1)
- starch (1)
- stemness (1)
- sterubin (1)
- stimulation (1)
- stratification (1)
- stromal cells (1)
- stromal tissues (1)
- subfoveal choroidal neovascularization (1)
- subretinal space (1)
- superfamily (1)
- supermolecular carrier systems (1)
- surgical oncology (1)
- systemic inflammatory response syndrome (1)
- t-cell recruting antibody constructs (1)
- targeted combination therapy (1)
- technology (1)
- therapy simulation (1)
- tight junction (1)
- tissue culture (1)
- tissue model (1)
- tissue preparation (1)
- tissue remodeling (1)
- toxicity (1)
- toxicology (1)
- trachea (1)
- tracheal cytotoxin (1)
- trafficking (1)
- transcapillary pressure gradient (1)
- transforming growth factor-beta 1 (1)
- translational research (1)
- translocation (1)
- transplantation (1)
- transport studies (1)
- tumor cells (1)
- tumor model systems (1)
- tumor test system (1)
- tumormicroenvironment (1)
- tumour (1)
- upcyte hepatocytes (1)
- validation (1)
- vascular normalization (1)
- vascular surgery (1)
- vascularized scaffold (1)
- vesicle-based barrier (1)
- viability (1)
- viral epidemiology (1)
- viral infection (1)
- virulence (1)
- weight-bearing (1)
- wound model (1)
- wound physiology (1)
- xenotransplantation (1)
- zielgerichtete Behandlung (1)
- zinc oxide nanoparticles (1)
- α-Cell (1)
- β-Cell (1)
Institute
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (149) (remove)
Sonstige beteiligte Institutionen
- Fraunhofer (1)
- Fraunhofer Institute Interfacial Engineering and Biotechnology (IGB) (1)
- Fraunhofer Institute for Integrierte Schaltungen (IIS) (1)
- IZKF (Interdisziplinäres Zentrum für Klinische Forschung), Universität Würzburg (1)
- Medizinische Universität Innsbruck (1)
- New York Blood Center (1)
- Queensland University of Technology (1)
Addition of heparin binding sites strongly increases the bone forming capabilities of BMP9 in vivo
(2023)
Highlights
• Despite not being crucial for bone development BMP9 can induce bone growth in vivo.
• BMP9 induced bone formation is strongly enhanced by introduced heparin binding sites.
• BMP9s bone forming capabilities are triggered by extracellular matrix binding.
• Heparin binding BMP9 (BMP9 HB) can improve the current therapies in treating bone fractures.
Abstract
Bone Morphogenetic proteins (BMPs) like BMP2 and BMP7 have shown great potential in the treatment of severe bone defects. In recent in vitro studies, BMP9 revealed the highest osteogenic potential compared to other BMPs, possibly due to its unique signaling pathways that differs from other osteogenic BMPs. However, in vivo the bone forming capacity of BMP9-adsorbed scaffolds is not superior to BMP2 or BMP7. In silico analysis of the BMP9 protein sequence revealed that BMP9, in contrast to other osteogenic BMPs such as BMP2, completely lacks so-called heparin binding motifs that enable extracellular matrix (ECM) interactions which in general might be essential for the BMPs' osteogenic function. Therefore, we genetically engineered a new BMP9 variant by adding BMP2-derived heparin binding motifs to the N-terminal segment of BMP9′s mature part. The resulting protein (BMP9 HB) showed higher heparin binding affinity than BMP2, similar osteogenic activity in vitro and comparable binding affinities to BMPR-II and ALK1 compared to BMP9. However, remarkable differences were observed when BMP9 HB was adsorbed to collagen scaffolds and implanted subcutaneously in the dorsum of rats, showing a consistent and significant increase in bone volume and density compared to BMP2 and BMP9. Even at 10-fold lower BMP9 HB doses bone tissue formation was observed. This innovative approach of significantly enhancing the osteogenic properties of BMP9 simply by addition of ECM binding motifs, could constitute a valuable replacement to the commonly used BMPs. The possibility to use lower protein doses demonstrates BMP9 HB's high translational potential.
Lung cancer is the main cause of cancer-related deaths worldwide. Despite the availability of several targeted therapies and immunotherapies in the clinics, the prognosis for lung cancer remains poor. A major problem for the low benefit of these therapies is intrinsic and acquired resistance, asking for pre-clinical models for closer investigation of predictive biomarkers for refined personalized medicine and testing of possible combination therapies as well as novel therapeutic approaches to break resistances.
One third of all lung adenocarcinoma harbor mutations in the KRAS gene, of which 39 % are transitions from glycine to cysteine in codon 12 (KRASG12C). Being considered “undruggable” in previous decades, KRASG12C-inhibitors now paved the way into the standard-of-care for lung adenocarcinoma treatment in the clinics. Still, the overall response rates as well as overall survival of patients treated with KRASG12C-inhibitors are sobering. Therefore, 3D KRASG12C-biomarker in vitro models were developed based on a decellularized porcine jejunum (SISmuc) using commercial and PDX-derived cell lines and characterized in regards of epithelial-mesenchymal-transition (EMT), stemness, proliferation, invasion and c-MYC expression as well as the sensitivity towards KRASG12C-inhibiton. The phenotype of lung tumors harboring KRAS mutations together with a c-MYC overexpression described in the literature regarding invasion and proliferation for in vivo models was well represented in the SISmuc models. A higher resistance towards targeted therapies was validated in the 3D models compared to 2D cultures, while reduced viability after treatment with combination therapies were exclusively observed in the 3D models. In the test system neither EMT, stemness nor the c-MYC expression were directly predictive for drug sensitivity. Testing of a panel of combination therapies, a sensitizing effect of the aurora kinase A (AURKA) inhibitor alisertib for the KRASG12C-inhibitor ARS-1620 directly correlating with the level of c-MYC expression in the corresponding 3D models was observed. Thereby, the capability of SISmuc tumor models as an in vitro test system for patient stratification was demonstrated, holding the possibility to reduce animal experiments.
Besides targeted therapies the treatment of NSCLC with oncolytic viruses (OVs) is a promising approach. However, a lack of in vitro models to test novel OVs limits the transfer from bench to bedside. In this study, 3D NSCLC models based on the SISmuc were evaluated for their capability to perform efficacy and risk assessment of oncolytic viruses (OVs) in a pre-clinical setting. Hereby, the infection of cocultures of tumor cells and fibroblasts on the SISmuc with provided viruses demonstrated that in contrast to a wildtype herpes simplex virus 1 (HSV-1) based OV, the attenuated version of the OV exhibited specificity for NSCLC cells with a more advanced and highly proliferative phenotype, while fibroblasts were no longer permissive for infection. This approach introduced SISmuc tumor models as novel test system for in vitro validation of OVs.
Finally, a workflow for validating the efficacy of anti-cancer therapies in 3D tumor spheroids was established for the transfer to an automated platform based on a two-arm-robot system. In a proof-of-concept process, H358 spheroids were characterized and treated with the KRASG12C-inhibitor ARS-1620. A time- and dose-dependent reduction of the spheroid area after treatment was defined together with a live/dead-staining as easy-to-perform and cost-effective assays for automated drug testing that can be readily performed in situ in an automated system.
Diese Arbeit hatte zum Ziel quantitative Analysen histologischer Aufnahmen der Haut nach unterschiedlichen Gesichtspunkten zu etablieren. Im ersten Abschnitt wurde die bildgestützte Quantifizierung der epidermalen Histomorphologie untersucht. Nach Sichtung und Beurteilung von 2145 hochauflösenden Fotografien HE-gefärbter Epidermis- und Vollhautmodellen jeglichen Zustands, wurde der BSGC-Score als Facettenklassifikation mit seinen insgesamt 40 Beurteilungskriterien aufgestellt. Die unterschiedlichen epidermalen Strata wurden mit Wichtungsfaktoren belegt. Die Bewertungskategorien sind mit einem Ampelsystem unterlegt. Eine Befundungsformel wurde aufgestellt. Weitere Bestandteile des BSGC-Scores sind eine Anleitung mit Bildbeilage sowie Dokumentationselemente. Die Anwendung erfolgte erfolgreich im Rahmen der Qualitätssicherung an Chargentests und zur Verlaufsbeurteilung eines In-vitro-Verbrennungsmodells aus humaner Epidermis durch Schneider et al. (2021) Der BSGC-Score dient als zügig durchführbares Evaluationstool zur Befundung von In-vitro-Epidermismodellen und nicht als diagnostisches Mittel. Der zweite Abschnitt beschäftigt sich mit der Vaskularisierung als Parameter der kutanen Wundheilung. Es wurden aSMA-IF-gefärbte Abbildungen porciner Verwundungsmodelle betrachtet und nach der Entfernung drüsiger Strukturen Gefäßanschnitte zu Beginn manuell ausgezählt. Hieraus wurden die nötigen Einstellungen für die Bildbearbeitungssoftware ImageJ ermittelt und die Abbildungen dieser anschließend zugeführt. Es erfolgte die automatisierte Quantifizierung elliptischer Formationen mit einer Größe ≥ 30 Pixel. Im nächsten Schritt wurden die Abbildungen in die Bereiche Wundrand, Wundgrund und Wundheilung unterteilt. In dem Bereich Wundheilung zeigte sich eine signifikant größere Revaskularisierung als in Wundgrund. Abschließend erfolgte der Vergleich sekundärer Wundauflagen. Der Vergleich der Quotienten Wundheilung/Wundgrund nicht-okklusiver und okklusiver Wundauflagen zeigte keinen signifikanten Unterschied in der Neovaskularisierung. Die isolierte Betrachtung der Revaskularisierung als einzelner Prozess der Wundheilung kann nicht als generelles Kriterium für die Gesamtbeurteilung dienen. Hier findet die gewählte Methodik ihre Limitation. Zukünftige Anwendungsbereiche des BSGC-Scores sind die Ausweitung auf Vollhautmodelle und andere Verwundungsmodalitäten. Eine automatisierte und durch eine KI-gestützte Befundung ist ebenfalls aufgrund des zugrundeliegenden umfangreichen Datensatzes denkbar. Auch kann eine automatisierte softwaregestützte Quantifizierung der Vaskularisierung als überblickende und zügige Beurteilung der Wundheilung sinnvoll erscheinen.
Infection research largely relies on classical cell culture or mouse models. Despite having delivered invaluable insights into host-pathogen interactions, both have limitations in translating mechanistic principles to human pathologies. Alternatives can be derived from modern Tissue Engineering approaches, allowing the reconstruction of functional tissue models in vitro. Here, we combined a biological extracellular matrix with primary tissue-derived enteroids to establish an in vitro model of the human small intestinal epithelium exhibiting in vivo-like characteristics. Using the foodborne pathogen Salmonella enterica serovar Typhimurium, we demonstrated the applicability of our model to enteric infection research in the human context. Infection assays coupled to spatio-temporal readouts recapitulated the established key steps of epithelial infection by this pathogen in our model. Besides, we detected the upregulation of olfactomedin 4 in infected cells, a hitherto unrecognized aspect of the host response to Salmonella infection. Together, this primary human small intestinal tissue model fills the gap between simplistic cell culture and animal models of infection, and shall prove valuable in uncovering human-specific features of host-pathogen interplay.
Despite promising clinical results in osteochondral defect repair, a recently developed bi-layered collagen/collagen-magnesium-hydroxyapatite scaffold has demonstrated less optimal subchondral bone repair. This study aimed to improve the bone repair potential of this scaffold by adsorbing bone morphogenetic protein 2 (BMP-2) and/or platelet-derived growth factor-BB (PDGF-BB) onto said scaffold. The in vitro release kinetics of BMP-2/PDGF-BB demonstrated that PDGF-BB was burst released from the collagen-only layer, whereas BMP-2 was largely retained in both layers. Cell ingrowth was enhanced by BMP-2/PDFG-BB in a bovine osteochondral defect ex vivo model. In an in vivo semi-orthotopic athymic mouse model, adding BMP-2 or PDGF-BB increased tissue repair after four weeks. After eight weeks, most defects were filled with bone tissue. To further investigate the promising effect of BMP-2, a caprine bilateral stifle osteochondral defect model was used where defects were created in weight-bearing femoral condyle and non-weight-bearing trochlear groove locations. After six months, the adsorption of BMP-2 resulted in significantly less bone repair compared with scaffold-only in the femoral condyle defects and a trend to more bone repair in the trochlear groove. Overall, the adsorption of BMP-2 onto a Col/Col-Mg-HAp scaffold reduced bone formation in weight-bearing osteochondral defects, but not in non-weight-bearing osteochondral defects.
Einleitung: Strukturelle Defekte der gastrointestinalen Hohlorgane stellen ein allgegen-wärtiges Problem im klinischen Alltag dar. Sie entstehen meist auf dem Boden einer ent-zündlichen oder tumorösen Grunderkrankung und können außerdem traumatisch sowie durch medizinische Eingriffe hervorgerufen werden. In der Folge kommt es zur Kontami-nation des umliegenden Gewebes mit Magen- bzw. Darminhalt, wodurch deletäre Folgen wie eine systemische Infektion, also eine Sepsis mit Multiorganversagen drohen können. Vor diesem Hintergrund sind gastrointestinale Defekte immer als potenziell lebensbedroh-lich für den Patienten zu betrachten. Die adäquate und kausale Behandlung erfolgt je nach Ätiologie und Zustand des Patienten durch eine Operation oder eine endoskopische Inter-vention. Hierzu stehen zahlreiche etablierte, operative und interventionelle Therapieme-thoden zur Verfügung. In manchen Fällen stoßen die etablierten Techniken jedoch an ihre Grenzen. Bei Patienten mit schwerwiegenden Komorbiditäten oder im Rahmen neuer me-dizinischer Verfahren sind Innovationen gefragt. Die Grundidee der vorliegenden Arbeit ist die Entwicklung einer biotechnologischen Therapieoption zur Versorgung gastrointesti-naler Hohlorganperforationen.
Methoden: Zur Durchführung einer Machbarkeitsstudie wurden zehn Göttinger Mi-nischweine in zwei Gruppen mit jeweils 5 Tieren aufgeteilt. Den Tieren der Experimental-gruppe wurden Hautbiopsien entnommen und daraus Fibroblasten isoliert, welche vo-rübergehend konserviert wurden. Unter Verwendung von azellularisiertem Schweinedarm erfolgte die Herstellung von Implantaten nach den Prinzipien des Tissue Engineerings. Die Tiere beider Gruppen wurden einer Minilaparotomie und einer ca. 3cm-Inzision der Ma-genvorderwand unterzogen. Die anschließende Versorgung wurde in der Experimental-gruppe durch Implantation der neuartigen Konstrukte erzielt. In der Kontrollgruppe wur-de im Sinne des Goldstandards eine konventionelle Naht durchgeführt. Anschließend wurden die Tiere für vier Wochen beobachtet. Eine bzw. zwei Wochen nach dem pri-mären Eingriff wurde bei allen Tieren beider Gruppen eine Laparoskopie bzw. Gastrosko-pie durchgeführt. Am Ende der klinischen Observationsphase wurden die Versuchstiere getötet und die entsprechenden Magenareale zur histologischen Untersuchung explantiert.
Ergebnisse: Die Herstellung der Implantate konnte auf der Basis standardisierter zellbio-logischer Methoden problemlos etabliert werden. Alle Tiere beider Gruppen überlebten den Primäreingriff sowie das vierwöchige Nachbeobachtungsintervall und zeigten dabei keine klinischen Zeichen möglicher Komplikationen. Die durchgeführten Laparoskopien und Gastroskopien ergaben bei keinem der Tiere Hinweise auf Leckagen oder lokale Infek-tionsprozesse. Die histologische Aufarbeitung zeigte im Bereich des ursprünglichen De-fekts eine bindegewebige Überbrückung sowie ein beginnendes Remodeling der Magen-schleimhaut in beiden Gruppen.
Schlussfolgerungen: Durch die Verknüpfung von Einzelprozessen der Zellkultur und dem Großtier-OP konnte ein neues Verfahren zum Verschluss gastrointestinaler Defekt erfolgreich demonstriert und etabliert werden. Das Projekt konnte reibungslos durchge-führt werden und lieferte Ergebnisse, die dem Goldstandard nicht unterlegen waren. Auf-grund der kleinen Fallzahl und weiterer methodischer Limitationen sind jedoch nur einge-schränkt Schlussfolgerungen möglich, weshalb die Durchführung größerer und gut geplan-ter Studien notwendig ist. Die Erkenntnisse dieser Pilotstudie liefern eine solide Basis für die Planung weiterführender Untersuchungen.
Due to the wide variety of benign and malignant salivary gland tumors, classification and malignant behavior determination based on histomorphological criteria can be difficult and sometimes impossible. Spectroscopical procedures can acquire molecular biological information without destroying the tissue within the measurement processes. Since several tissue preparation procedures exist, our study investigated the impact of these preparations on the chemical composition of healthy and tumorous salivary gland tissue by Fourier-transform infrared (FTIR) microspectroscopy. Sequential tissue cross-sections were prepared from native, formalin-fixed and formalin-fixed paraffin-embedded (FFPE) tissue and analyzed. The FFPE cross-sections were dewaxed and remeasured. By using principal component analysis (PCA) combined with a discriminant analysis (DA), robust models for the distinction of sample preparations were built individually for each parotid tissue type. As a result, the PCA-DA model evaluation showed a high similarity between native and formalin-fixed tissues based on their chemical composition. Thus, formalin-fixed tissues are highly representative of the native samples and facilitate a transfer from scientific laboratory analysis into the clinical routine due to their robust nature. Furthermore, the dewaxing of the cross-sections entails the loss of molecular information. Our study successfully demonstrated how FTIR microspectroscopy can be used as a powerful tool within existing clinical workflows.
Bone morphogenetic proteins (BMPs) are involved in various aspects of cell-cell communication in complex life forms. They act as morphogens, help differentiate different cell types from different progenitor cells in development, and are involved in many instances of intercellular communication, from forming a body axis to healing bone fractures, from sugar metabolism to angiogenesis. If the same protein or protein family carries out many functions, there is a demand to regulate and fine-tune their biological activities, and BMPs are highly regulated to generate cell- and context-dependent outcomes.
Not all such instances can be explained yet. Growth/differentiation factor (GDF)5 (or BMP14) synergizes with BMP2 on chondrogenic ATDC5 cells, but antagonizes BMP2 on myoblastic C2C12 cells. Known regulators of BMP2/GDF5 signal transduction failed to explain this context-dependent difference, so a microarray was performed to identify new, cell-specific regulatory components. One identified candidate, the fibroblast growth factor receptor (FGFR)2, was analyzed as a potential new co-receptor to BMP ligands such as GDF5: It was shown that FGFR2 directly binds BMP2, GDF5, and other BMP ligands in vitro, and FGFR2 was able to positively influence BMP2/GDF5-mediated signaling outcome in cell-based assays. This effect was independent of FGFR2s kinase activity, and independent of the downstream mediators SMAD1/5/8, p42/p44, Akt, and p38. The elevated colocalization of BMP receptor type IA and FGFR2 in the presence of BMP2 or GDF5 suggests a signaling complex containing both receptors, akin to other known co-receptors of BMP ligands such as repulsive guidance molecules.
This unexpected direct interaction between FGF receptor and BMP ligands potentially opens a new category of BMP signal transduction regulation, as FGFR2 is the second receptor tyrosine kinase to be identified as BMP co-receptor, and more may follow. The integration of cell surface interactions between members of the FGF and BMP family especially may widen the knowledge of such cellular communication mechanisms which involve both growth factor families, including morphogen gradients and osteogenesis, and may in consequence help to improve treatment options in osteochodnral diseases.
Für die Verwendung von zellbasierten Therapeutika ist vor allem die korrekt Identifikation
sowohl vom Ausgangsmaterial wie auch dem produziertem Material von
zentraler Wichtigkeit. In dieser Arbeit wurde eine Methodik entwickelt, welche eine
nicht-invasive Klassifizierung von Zellen und zellulärer Entwicklung aufgrund ihrer
zweidimensionalen Magnetresonanz-Korrelationsspektren ermöglichte.
Hierzu wurde ein mobiler MR-Scanner mit einer Feldstärke von 0.5T und einem Isozentrum
von 1 cm3 verwendet. Aufgrund der kompakten und leichten Bauweise war
es möglich, das System in normalen Zellkulturlaboren zu verwenden. Von den Proben
wurde ein zweidimensionales T1/T2 -Korrelationsspektrum aufgenommen, anhand
dessen die Zellen klassifiziert werden sollten. Mithilfe von Agarose-Dotagraf® -Zell-
Phantomen konnte die Stabilität und Reproduzierbarkeit des Messsystems und der
verwendeten Sequenz validiert werden.
Aufgrund der unter Umständen recht langen Messzeiten der MR-Technologie war
auch die Handhabung und Kultur der Zellproben während des Messprozesses von
großer Bedeutung. Um hierfür den Durchsatz an Proben zu erhöhen, wurde eine kostengünstige
und ebenfalls mobile Robotikanlage entwickelt. Diese basierte auf dem
kommerziell erhältlichen Roboterarm Braccio, welcher durch einen Arduino Mega
Mikrocontroller gesteuert wurde. Mit bis zu 24 Proben pro Tag konnte durch die
Automatisierung der Durchsatz an Proben um den Faktor 3 – 4 gesteigert werden.
Durch den entwickelten Prozess war es möglich, eine umfangreiche Datenbank –
bestehend aus 362 unabhängigen Messungen (biologische Replikate) – aufzubauen.
Die Datenbank enthielt Messungen von zehn unterschiedlichen Zelllinien. Zusätzlich
wurden T1/T2 -Korrelationsspektren von mesenchymalen Stromazellen (MSCs)
vor und nach deren Differenzierung zu Adipocyten aufgenommen, um ihre zelluläre
Entwicklung nicht-invasiv charakterisieren zu können.
Die aufgenommenen Daten wurden mithilfe einer geeigneten Support Vector Machine
wie auch angepassten künstlichen neuronalen Netzwerken klassifiziert. Mithilfe
dieser Methoden konnten die Zelllinien und MSCs anhand ihrer aufgenommenen
Korrelationsspektren mit einer Genauigkeit von bis zu 98% klassifiziert werden.
Diese hohe Treffsicherheit legte den Schluss nahe, dass die Kombination aus nichtinvasiver,
zweidimensionaler T1/T2 -MR-Relaxometrie und der Verwendung von geeigneten
Methoden des machine learning und der künstlichen Intelligenz eine effiziente
Methodik für die nicht-invasive Klassifizierung von Zellen sowie zellulärer
Entwicklung darstellt.
Efficient redirection of NK cells by genetic modification with chemokine receptors CCR4 and CCR2B
(2023)
Natural killer (NK) cells are a subset of lymphocytes that offer great potential for cancer immunotherapy due to their natural anti-tumor activity and the possibility to safely transplant cells from healthy donors to patients in a clinical setting. However, the efficacy of cell-based immunotherapies using both T and NK cells is often limited by a poor infiltration of immune cells into solid tumors. Importantly, regulatory immune cell subsets are frequently recruited to tumor sites. In this study, we overexpressed two chemokine receptors, CCR4 and CCR2B, that are naturally found on T regulatory cells and tumor-resident monocytes, respectively, on NK cells. Using the NK cell line NK-92 as well as primary NK cells from peripheral blood, we show that genetically engineered NK cells can be efficiently redirected using chemokine receptors from different immune cell lineages and migrate towards chemokines such as CCL22 or CCL2, without impairing the natural effector functions. This approach has the potential to enhance the therapeutic effect of immunotherapies in solid tumors by directing genetically engineered donor NK cells to tumor sites. As a future therapeutic option, the natural anti-tumor activity of NK cells at the tumor sites can be increased by co-expression of chemokine receptors with chimeric antigen receptors (CAR) or T cell receptors (TCR) on NK cells can be performed in the future.